The antibody is optimized for:
| Application | Recommended Dilution | Validation |
|---|---|---|
| Western Blot (WB) | 1:1000–1:4000 | Detected in MCF-7 cells |
| Immunoprecipitation (IP) | 0.5–4.0 µg per 1.0–3.0 mg lysate | Tested in HepG2 cells |
| Immunohistochemistry (IHC) | 1:50–1:500 | Human lung cancer tissue (antigen retrieval with TE buffer pH 9.0 or citrate buffer pH 6.0) |
| ELISA | N/A (protocol available) | N/A |
Note: Titration is recommended for optimal results .
CCDC59 exhibits nucleolar and cytoplasmic expression across diverse tissues, including:
Brain: Cerebellum, cerebral cortex, hippocampus.
Blood: Leukocytes.
Cancer: Overexpression in breast, lung, and pancreatic cancer .
CCDC59 interacts with transcription factors (e.g., Nkx-2.1) to enhance surfactant protein B (SFTPB) and C (SFTPC) promoter activities, critical for lung function .
Elevated CCDC59 expression is observed in malignancies, suggesting roles in oncogenesis or tumor progression .
Antibody-based targeting may offer diagnostic or therapeutic potential, though mechanisms remain under investigation .